Search clinical trials for: Human immunoglobulin intravenous

Total 10679 results

University of Colorado, Denver
Veloxis Pharmaceuticals

Terminated

Pilot Study of Treatment for Subclinical AMR (Antibody-mediated Rejection) in Kidney Transplant Recipients

Kidney Transplant Rejection

United States
Fred Hutchinson Cancer Research Center/University...
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Mary Feng, MD
AstraZeneca

Recruiting

Hypofractionated Radiotherapy Followed by Durvalumab With or Without Tremelimumab for Liver Cancer After Progression on PD-1 Inhibition

Advanced Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma...

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery

Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Metastatic Carcinoma in the Liver | Resectable Mass

United States
Proclara Biosciences, Inc.

Completed

A Study of NPT189 in Healthy Subjects

Amyloidosis

Netherlands
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Durvalumab and Grid Therapy for Non-small Cell Lung Cancer in Progression During or After Treatment With PACIFIC Regimen

Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8

United States
Federal Research Institute of Pediatric Hematology...

Recruiting

Evaluation of Subcutaneous Immunoglobulin Product Cutaquig in Terms of Safety and Efficacy in the Treatment of Patients With Primary Immunodeficiencies

Primary Immunodeficiency Diseases (PID)

Russian Federation
Grifols Therapeutics LLC

Terminated

Tetanus Immunization in Subjects With No Immunization History or With Tetanus Antibody Levels Below Protective Levels

Tetanus

United States
Emory University
National Cancer Institute (NCI)

Recruiting

Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides

Mycosis Fungoides | Sezary Syndrome | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma

United States
Rutgers, The State University of New Jersey

Recruiting

Immunoglobulin G Therapy Dose Optimization

Obesity | Immune Deficiency

United States
A.O. Ospedale Papa Giovanni XXIII
Aferetica - Italy (BO)

Terminated

Convalescent Antibodies Infusion in Critically Ill COVID 19 Patients

Coronavirus Infection | Pneumonia, Ventilator-Associated

Italy
Crucell Holland BV

Completed

Rabies Virus Neutralizing Activity and Safety of CL184, a Monoclonal Antibody Cocktail, in Simulated Rabies Post-Exposure Prophylaxis in Healthy Adults

Rabies

India
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma

Sezary Syndrome | Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8 | Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8 | Transformed Mycosis Fungoides | Folliculotropic... and other conditions

United States
University of South Florida
Baxter Healthcare Corporation

Unknown

An Open-label Trial of Intravenous Immune Globulin (IVIG)in Treating Spinocerebellar Ataxias

Spinocerebellar Ataxias

United States
Northwestern University
National Cancer Institute (NCI); AstraZeneca; MedImmune LLC

Completed

Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma

Malignant Glioma | Recurrent Glioblastoma

United States
Piero Luigi Ruggenenti
Aferetica

Withdrawn

Convalescent Antibodies Infusion in COVID 19 Patients

Pneumonia, Viral | Corona Virus Infection
CSL Behring

Terminated

Pharmacokinetics, Safety, and Tolerability of CSL760, an Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin, in Healthy Adult Subjects

Coronavirus Disease 2019 (COVID-19)

Australia
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma

Malignant Solid Neoplasm | Melanoma | Colitis | Lung Non-Small Cell Carcinoma | Malignant Genitourinary System Neoplasm

United States
University Hospital Tuebingen
Universität Tübingen

Completed

Immunglobulin M Enriched Intra Venous Immunoglobulin (IVIG) Therapy in Adult Respiratory Distress Syndrom (ARDS) Patients (IVIG)

Septic Shock | Respiratory Distress Syndrome, Adult

Germany
Medical University of Vienna

Completed

Biseko Versus Albumin in Systemic Inflammatory Response Syndrome (SIRS) Patients

Systemic Inflammatory Response Syndrome

Austria
Fred Hutchinson Cancer Center

Recruiting

Ustekinumab for the Prevention of Acute Graft-versus-Host Disease After Unrelated Donor Hematopoietic Cell Transplant

Hematopoietic and Lymphoid System Neoplasm | Hematologic and Lymphocytic Disorder

United States
Imperial College London
Cambridge University Hospitals NHS Foundation Trust; National Institute for... and other collaborators

Active, not recruiting

Transplant Antibody-Mediated Rejection: Guiding Effective Treatments (TAR:GET-1)

Kidney Transplant Rejection | Antibody-mediated Rejection

United Kingdom
Assistance Publique - Hôpitaux de Paris
Fondation Centaure

Completed

Bortezomib in Rejection of Kidney Transplants (TRIBUTE)

Chronic Antibody-mediated Transplant Rejection

France
Avicenna Research Institute
Tehran University of Medical Sciences

Completed

Menstrual Blood Stem Cells in Severe Covid-19

Covid19 | Cytokine Storm

Iran, Islamic Republic of
University of Wisconsin, Madison
Prostate Cancer Foundation; Madison Vaccines, Inc

Completed

Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer

Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Metastatic Malignant Neoplasm in the Bone | Metastatic Malignant Neoplasm in the Soft Tissues | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate Cancer

United States
Proclara Biosciences, Inc.

Terminated

Multiple Ascending Dose Study in Healthy Subjects

Amyloidosis

Netherlands
Celularity Incorporated
Celgene Corporation

Completed

A Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease

Crohn's Disease

United States
Roswell Park Cancer Institute
AstraZeneca

Active, not recruiting

Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation

BRCA1 Gene Mutation | BRCA2 Gene Mutation | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Serous Adenocarcinoma

United States
Instituto Grifols, S.A.

Completed

Study to Evaluate the Safety and Efficacy of High Dose IVIG in Hospitalized Participants With Coronavirus Disease (COVID-19)

COVID-19

Spain
Sandeep Jain, MD

Completed

IVIG-eye Drops Treatment for Dry Eye Disease

Dry Eye

United States
Vera Bril

Unknown

Panzyga in CIDP Administered at Different Infusion Rates (Panzyga-CIDP)

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Canada
Jonsson Comprehensive Cancer Center
AstraZeneca

Active, not recruiting

Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer

Stage IV Bladder Cancer AJCC v8 | Stage IVA Bladder Cancer AJCC v8 | Stage IVB Bladder Cancer AJCC v8 | Bladder Urothelial Carcinoma

United States
Jonsson Comprehensive Cancer Center
AstraZeneca

Active, not recruiting

Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies

Metastatic Malignant Female Reproductive System Neoplasm | Platinum-Resistant Malignant Female Reproductive System Neoplasm | Recurrent Malignant Female Reproductive System Neoplasm | Refractory Malignant Female Reproductive System Neoplasm

United States
Deepa Manwani

Recruiting

Intravenous Gammaglobulin for Sickle Cell Pain Crises

Pain | Sickle Cell Disease

United States
University of Colorado, Denver
Children's Hospital Los Angeles

Recruiting

Therapies for Down Syndrome Regression Disorder

Down Syndrome | Regression

United States
Hansa Biopharma AB

Completed

A Study of Imlifidase in Patients With Guillain-Barré Syndrome

Guillain-Barré Syndrome (GBS)

France, Netherlands, United Kingdom
Zhejiang University
Hangzhou Occupational Disease Prevention Hospital

Unknown

Three Measures for the Prevention of Carious Lesions in Preschool Children

Dental Caries

China
University Hospital Southampton NHS Foundation...
University College London Hospitals; University of Wisconsin, Madison; University... and other collaborators

Recruiting

Phase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed/Refractory Neuroblastoma (MiniVan)

Neuroblastoma

United Kingdom, United States
Jaehoon Ko

Recruiting

Intravenous Immunoglobulin Replacement Therapy for Persistent COVID-19 in Patients With B-cell Impairment

COVID-19

Korea, Republic of
Takeda

Active, not recruiting

A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Participants

Primary Immunodeficiency Diseases (PID)

Japan
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Terminated

Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Steroid-Refractory Pneumonitis

United States
Prothya Biosolutions

Completed

Intravenous Immunoglobulin (IVIg) for Parvovirus B19(PVB19) Mediated Cardiomyopathy

Myocardial Diseases | Parvovirus B19, Human

Netherlands
Grifols Therapeutics LLC

Completed

Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis (PRIVIG)

Multiple Sclerosis, Relapsing-Remitting

Canada, Israel, United States, Austria, Czech Republic, Germany, Greece, Hungary, Poland, Slovakia, Sweden, United Kingdom
University of Texas

Terminated

Randomized Study of Intravenous Immunoglobulin in Patients With Mild or Moderate Myasthenia Gravis

Myasthenia Gravis
Takeda

Completed

A Study of TAK-771 in Japanese People With Primary Immunodeficiency Diseases (PID)

Primary Immunodeficiency Diseases (PID)

Japan
Emory University

Terminated

Randomized Study of Plasmapheresis or Human Immunoglobulin Infusion in Childhood Guillain-Barre Syndrome

Guillain-Barre Syndrome
National Center for Research Resources (NCRR)
University of Vermont

Completed

Phase III Multicenter Double Blind Controlled Trial of Human Immune Globulin Therapy in Previously Untreated Patients With Chronic Inflammatory Demyelinating Neuropathy

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
National Center for Research Resources (NCRR)
Ohio State University

Completed

Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Chronic Inflammatory Demyelinating Polyneuropathy

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Alfred Chung, MD
AbbVie; Janssen Pharmaceuticals

Recruiting

Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE)

AL Amyloidosis | Light Chain (AL) Amyloidosis | Systemic Light Chain Disease

United States

Search clinical trials for: Human immunoglobulin intravenous

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Nigeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations